BioSpace News Archive

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 89,559 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees.

Soligenix, Inc. announced the pricing of its public offering of 6,538,500 shares of common stock and warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30 per share and accompanying warrant for aggregate gross proceeds of approximately $8.5 million, before deducting placement agent fees and other offering expenses.

The Feinstein Institutes for Medical Research has selected two scientists from the University of Texas Southwestern Medical Center, Helen H. Hobbs, MD, and Jonathan C. Cohen, PhD, to receive the 10th annual Ross Prize in Molecular Medicine for groundbreaking research in dyslipidemias and metabolic liver disease.

FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint.

Curis, Inc. today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Development Officer, Jonathan B. Zung , Ph.D. to purchase a total of 500,000 shares of Curis common stock, with a grant date of May 1, 2023 (the “Inducement Grant”).

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023, on Friday, May 12, 2023.

Twist Bioscience Corporation today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open.

Impel Pharmaceuticals Inc. announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.

VolitionRx Limited announced it will host a conference call on Thursday May 11 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the first quarter 2023, in addition to providing a business update.